(Q36746749)

16 August 2017

NY-ESO-1 antibody as a novel tumour marker of gastric cancer (English)

1 reference

16 August 2017

S Fujiwara

1

1 reference

16 August 2017

H Wada

2

1 reference

16 August 2017

J Kawada

3

1 reference

16 August 2017

R Kawabata

4

1 reference

16 August 2017

T Takahashi

5

1 reference

16 August 2017

J Fujita

6

1 reference

16 August 2017

T Hirao

7

1 reference

16 August 2017

K Shibata

8

1 reference

16 August 2017

Y Makari

9

1 reference

16 August 2017

S Iijima

10

1 reference

16 August 2017

H Nishikawa

11

1 reference

16 August 2017

A A Jungbluth

12

1 reference

16 August 2017

Y Nakamura

13

1 reference

16 August 2017

Y Kurokawa

14

1 reference

16 August 2017

M Yamasaki

15

1 reference

16 August 2017

H Miyata

16

1 reference

16 August 2017

K Nakajima

17

1 reference

16 August 2017

S Takiguchi

18

1 reference

16 August 2017

E Nakayama

19

1 reference

16 August 2017

M Mori

20

1 reference

16 August 2017

Y Doki

21

1 reference

16 August 2017

language of work or name

English

0 references

publication date

12 February 2013

1 reference

British Journal of Cancer

16 August 2017

1 reference

16 August 2017

108

1 reference

16 August 2017

5

1 reference

16 August 2017

1119-1125

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.2013.51

16 August 2017

0 references

cites work

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619069

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619069

A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619069

Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619069

T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619069

NY-ESO-1: review of an immunogenic tumor antigen

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619069

Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619069

A survey of the humoral immune response of cancer patients to a panel of human tumor antigens

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619069

Effect of Age and Cigarette Smoking on Carcinoembryonic Antigen Levels

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619069

Correlation of high and decreased NY-ESO-1 immunity to spontaneous regression and subsequent recurrence in a lung cancer patient.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619069

NY-ESO-1 expression and immunogenicity in prostate cancer patients

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619069

Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619069

The utility of pre-operative peritoneal lavage examination in serosa-invading gastric cancer patients.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619069

Prediction of peritoneal metastasis in advanced gastric cancer by gene expression profiling of the primary site.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619069

NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619069

Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619069

The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619069

Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1

5 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2013.51

p53 antibodies in patients with various types of cancer: assay, identification, and characterization

21 January 2018

1 reference

12 December 2020

Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers.

1 reference

12 December 2020

Autoantibodies in breast cancer: their use as an aid to early diagnosis

1 reference

12 December 2020

Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination

1 reference

12 December 2020

Comparison of time trends in stomach cancer incidence (1973-2002) in Asia, from Cancer Incidence in Five Continents, Vols IV-IX

1 reference

12 December 2020

Role of FDG-PET/CT in follow-up of patients treated with resective gastric surgery for tumour

1 reference

12 December 2020

Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma

1 reference

12 December 2020

The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study

1 reference

12 December 2020

Prognostic significance of tumor markers in peritoneal lavage in advanced gastric cancer

1 reference

12 December 2020

Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers

1 reference

12 December 2020

Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma

1 reference

12 December 2020

Tumour markers in prostatic carcinoma. A comparison of prostate-specific antigen with acid phosphatase

1 reference

12 December 2020

Carcinoembryonic antigen (CEA) in stage IV gastric cancer as a risk factor for liver metastasis: a univariate and multivariate analysis

1 reference

12 December 2020

Factors influencing growth rate of recurrent stomach cancers as determined by analysis of serum carcinoembryonic antigen

1 reference

12 December 2020

Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.2013.51

1 reference

Dimensions Publication ID

16 August 2017

0 references

1 reference

16 August 2017

PubMed publication ID

23403818

1 reference